Enabling a new nanoparticle based ADC (antibody-drug conjugated) like approach to deliver drug candidates able to significantly reposition and enhance both existing and developing cancer (and other) therapies.

NanoValent Pharmaceuticals, Inc. (NVP), founded in 2006, is a privately-held company collaborating with the Children’s Hospital Los Angeles (CHLA) as well as other US academic partners. NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational capability.